• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

4D Pharma

Pharma & Human Health

MHRA and HPRA Clear 4D Pharma’s Blautix Phase II Study

June 14, 2018 Microbiome Times

4D pharma plc announced that the Company has received clearance from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority (HPRA) to commence the Phase II study of Blautix, the […]

Pharma & Human Health

4D pharma plc enters into clinical collaboration agreement with MSD

June 13, 2018 Microbiome Times

4D pharma plc (AIM: DDDD), a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products, today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) […]

Pharma & Human Health

Monotherapy Trial Approved; the First Live Biotherapeutic Trial in Cancer

May 21, 2018 Microbiome Times

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company has submitted, and the Medicines and Healthcare products Regulatory Agency (MHRA) has cleared, a Clinical Trial […]

Pharma & Human Health

FDA Clears 4D Pharma’s IND Application for Blautix

May 9, 2018 Microbiome Times

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that the Company has submitted, and the U.S. Food and Drug Administration (FDA) has cleared, an Investigational New […]

QIAGEN’S NEW HIGH-THROUGHPUT BENCHTOP AUTOMATION SYSTEM

Sign Up to Free Newsletter

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
  • Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
    November 17, 2025
sign up

Sign up to the Microbiome Times newsletter